Pair of COVID-19 vaccine candidates move on to next trial phases

Jul 20, 2020 - 02:39 PM
COVID19 Web Sized

A COVID-19 trial vaccine developed by the University of Oxford and AstraZeneca produced neutralizing antibody responses in patients with SARS-CoV-2, according to a study published July 20 in The Lancet. An immune response was detected in 32 of 35 participants after one dose and in all participants after a booster dose.

The trial will now proceed to phases two and three. Oxford/AstraZeneca in May announced it will provide the U.S. with 300 million initial doses and the U.K. 100 million initial doses this fall.

In a separate vaccine study by CanSino Biologics, also released today, a phase two test in Wuhan, China, showed an immunity response in 508 participants. The study said healthy adults may only need one dose, while older adults may need two to induce a better immune response. Results showed minimal adverse reactions; the candidate will now move to phase three testing.

Related News Articles

Headline
FDA announces recall of cefazolin by Sandoz for mislabeling
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…
Headline
COVID-19 vaccination approved for older adults and high-risk, younger children
 The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
OSHA proposes removing remaining requirements of its COVID-19 emergency temporary standard
The Occupational Safety and Health Administration June 30 released a proposed rule to remove what remains of its emergency temporary standard for occupational…
Headline
RFK Jr. says CDC will no longer recommend COVID-19 vaccine for healthy children, pregnant women
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…
Headline
FDA to limit COVID-19 vaccine to people over 65, others at high risk for serious illness
Leaders of the Food and Drug Administration May 20 announced new guidelines for administering the COVID-19 vaccine in a paper published by the New England…
Headline
Study finds driving with COVID-19 raises crash risk by 25%
A study published April 8 by the Public Library of Science’s Journal of Global Public Health found that driving while infected with COVID-19 raises the risk of…